Ambient Temperature Stable, Scalable COVID-19 Polymer Particle Vaccines Induce Protective Immunity.

"Conflict of Interest B.H.A.R is inventor of the BP technology and co‐founder/shareholder of Polybatics Ltd that commercializes BP‐based products. The other authors declare no conflict of interest."

"The authors thank Dr. David Wibowo and Dr. Raisa Monteiro at Griffith Institute for Drug Discovery, Griffith University, for assisting with animal trials and editorial assistance, respectively. The authors also thank Dr. Alyssa Pyke, Queensland Health, Brisbane, for providing the QLD02 SARS‐CoV‐2 virus isolate. B.H.A.R. is funded by Fast Grants Award #2165 (Emergent Ventures at Mercatus Center, George Mason University, USA), the Australian Research Council (ARC) Discovery Project (DP200100874), the ARC Linkage Infrastructure, Equipment and Facilities (LE20010014) and Griffith University. The authors acknowledge the facilities, and the scientific and technical assistance, of the Australian Microscopy and Microanalysis Research Facility at the Centre for Microscopy and Microanalysis, as well as the Centre for Clinical Research and the Metabolomics Australia—Queensland Node at the University of Queensland. A.S. was supported by an Investigator grant from the National Health and Medical Research Council of Australia (APP1173880) and is a member of the AIDRC Global Virus Network (GVN) Center of Excellence. The authors thank Clive Berghofer and Lyn Brazil (and others) for their generous philanthropic donations that funded the establishment of the PC3 (BSL3) SARS‐CoV‐2 research facility at QIMR Berghofer MRI."